Translationally, the use of a therapeutic treatment of PF that putatively targets SREBP2 could possibly limit both the innate immune response and partial EndoMT in the lung, thereby alleviating the pathophysiological consequence due to early lung injury. The gene discussed is SREBF2; the disease is pemphigus foliaceus.